REFERENCES
- Angell, M. 2009. Drug companies & doctors: A story of corruption. The New York Review of Books. Available at: http://www.nybooks.com/articles/archives/2009/jan/15/drug-companies-doctorsa-story-of-corruption/?pagination=false (accessed November 9, 2015).
- Barton, D., T. Stossel, and L. Stell. 2014. After 20 years, industry critics bury skeptics, despite empirical vacuum. International Journal of Clinical Practice 68(6):666–673. doi:10.1111/ijcp.12438.
- Bero, L. A., and Q. Grundy. 2016. Why having a (nonfinancial) interest is not a conflict of interest. PLoS Biology 14(12):e2001221.
- DuBois, J. M., E. A. Anderson, J. T. Chibnall, J. Mozersky, and H. A. Walsh. 2019. Serious ethical violations in medicine: A statistical and ethical analysis of 280 cases in the United States from 2008–2016. American Journal of Bioethics 19(1):XX–XX.
- Rodwin, M. 2012. Conflicts of interest, institutional corruption, and pharma: An agenda for reform. The Journal of Law, Medicine & Ethics 40(3):511–522. doi:10.1111/j.1748-720X.2012.00683.x.
- Rodwin, M. A. 2018. Attempts to redefine conflicts of interest. Accountability in Research 25(2):67–78.
- Shaywitz, D., and T. Stossel. 2009. It's time to fight the ‘pharmascolds’. Wall Street Journal, April 8. Available at: https://www.wsj.com/articles/SB123914780537299005 (accessed October 13, 2015).
- Stell, L. 2010. Avoiding over-deterrence in managing physicians’ relationships with industry. American Journal of Bioethics 10(1):27–29. doi:10.1080/15265160903441129.
- Wiersma, M., I. Kerridge, and W. Lipworth. 2018. Should we try to manage non-financial interests? Yes. Head to head article. British Medical Journal 361:k1240.